Compounds > sklb1002
Page last updated: 2024-08-03 22:13:02

sklb1002

Description

SKLB1002: structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID71461003
CHEMBL ID2180603
MeSH IDM0591431

Synonyms (32)

Synonym
bdbm50399536
CHEMBL2180603 ,
S7258
1225451-84-2
sklb1002
HY-13944
CS-1807
K0060
c13h12n4o2s2
2-((6,7-dimethoxyquinazolin-4-yl)thio)-5-methyl-1,3,4-thiadiazole
AC-33004
J-004821
AKOS026750477
EX-A319
HMS3653M04
sklb1002, >=98% (hplc)
SW220084-1
mfcd27938707
FT-0700126
BS-14631
2-[(6,7-dimethoxyquinazolin-4-yl)thio]-5-methyl-1,3,4-thiadiazole
6,7-dimethoxy-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]quinazoline
BCP09480
sklb-1002
SB19354
2-(6,7-dimethoxyquinazolin-4-yl)sulfanyl-5-methyl-1,3,4-thiadiazole
CCG-267711
H11010
NCGC00378568-07
A891099
AZB45184
6,7-dimethoxy-4-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]quinazoline

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Vascular endothelial growth factor receptor 2Homo sapiens (human)IC500.0320AID710632

Bioassays (7)

Assay IDTitleYearJournalArticle
AID710558Antitumor activity against human HepG2 cells xenografted mouse assessed as inhibition of tumor growth at 100 mg/kg qd for 18 days2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
ISSN: 1520-4804		Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
AID710619Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 10 uM2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
ISSN: 1520-4804		Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
AID710632Inhibition of VEGFR22012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
ISSN: 1520-4804		Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
AID710618Antiangiogenic activity in zebrafish embryos assessed as inhibition of intersegmental vessel growth at 2.5 uM2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
ISSN: 1520-4804		Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
AID710617Antitumor activity against human SW620 cells xenografted mouse assessed as inhibition of tumor growth at 100 mg/kg qd for 18 days2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
ISSN: 1520-4804		Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
vatalanib
1
monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist		2012201212.0low000010
telatinib
1
2012201212.0medium000010
cp 547632
1
2012201212.0medium000010
lenvatinib
1
aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist		2012201212.0low000010
ki23057
1
2012201212.0high000010
osi 930
1
aromatic amide2012201212.0medium000010
tivozanib
1
aromatic ether2012201212.0low000010
cediranib
1
aromatic ether2012201212.0low000010
aee 788
1
6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug		2012201212.0low000010
motesanib
1
pyridinecarboxamide2012201212.0medium000010
tak 593
1
2012201212.0medium000010
gsk 1363089
1
aromatic ether2012201212.0low000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
quinazolines
4
azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines		201120209.5high000040
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Angiogenesis, Pathologic0
2
2011201312.0low000020
B16 Melanoma0
1
2011201113.0low000010
Benign Neoplasms0
2
2011201212.5low000020
Breast Cancer0
1
2014201410.0low000010
Breast Neoplasms0
1
2014201410.0low000010
Burns, Chemical0
1
202020204.0low000010
Cancer of Colon0
1
2014201410.0low000010
Colonic Neoplasms0
1
2014201410.0low000010
Corneal Diseases0
1
202020204.0low000010
Disease Models, Animal0
3
201320208.3medium000030
Inflammation0
1
2013201311.0low000010
Innate Inflammatory Response0
1
2013201311.0low000010
Invasiveness, Neoplasm0
1
2011201113.0low000010
Necrosis0
1
2014201410.0low000010
Neoplasms0
2
2011201212.5low000020
Palmoplantaris Pustulosis0
1
2013201311.0low000010
Psoriasis0
1
2013201311.0low000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019